News
Abzena receives growth capital investment from newly launched Biospring Partners
Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.
The new capital...
News
CPhI Japan rescheduled for Spring 2021 with digital solutions to be launched
CPhI Japan organised by Informa Markets announces that, following a detailed review with partners and key industry stakeholders and to ensure the health and safety of our community, the event will be postponed until *April 14-16, 2021.
The event organiser’s...
News
Optimus Pharma gets nod from DGCI to make COVID-19 drug ‘Favicovid’
Optimus Pharma said it has received the Drugs Controller General of India (DCGI) approval to manufacture and market Favipiravir 200 mg tablets for the treatment of patients with mild to moderate COVID-19.
The drug regulator also approved the company’s subsidiary...
Drug Research
Seven Indian Drugmakers Race To Develop Covid-19 Vaccine
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E among domestic pharma firms working on the vaccines in India
At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they...
News
Dm-drogerie markt opens a new distribution center in Germany: with robotics & software from Swisslog
The first pallet leaving the center in Wustermark headed for our dm drugstores marks a milestone,” said Christoph Werner, Chairman of the dm Board, in Karlsruhe on May 19; referencing the coronavirus crisis, he continued: “Considering the current situation,...
Clinical Trials
Lilly’s Mirikizumab Superior to Cosentyx in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx...
News
Merck, contract research firm IRBM partner on coronavirus therapies
Merck (MSD) has collaborated with contract research services company IRBM for the identification and development of new peptide therapeutics that can target various strains of coronavirus, including SARS-CoV-2.
The alliance will work on hit to lead optimisation and preclinical development...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.